Preview

Obstetrics, Gynecology and Reproduction

Advanced search

Retrospective comparative study on artificial reproductive technology outcomes in women undergoing in vitro fertilization with recombinant gonadotropins

https://doi.org/10.17749/2313-7347/ob.gyn.rep.2022.304

Abstract

Introduction. Currently, various hormonal preparations are used in assisted reproductive technology (ART) programs which allow to profoundly improve protocols for stimulating superovulation.

Aim: to comparatively analyze effectiveness of recombinant follicle-stimulating hormone preparations in in vitro fertilization (IVF) and embryo transfer (ET) programs.

Materials and Methods. In order to evaluate the effectiveness of gonadotropic drugs, a retrospective analysis of 75 outpatient medical records after routine infertility treatment with IVF and ET programs using follitropin alfa (Gonal-F®), follitropin beta (Puregon®), biosimilar follitropin alfa (Primapur®) for ovarian stimulation was performed. Women examined were divided evenly into groups of 25 patients receiving each drug. The main efficiency indicators of IVF and PE cycles were as follows: the number of aspirated oocytes, the number of embryos obtained, the percentage of clinical pregnancy, as well as «Take Home Baby» parameter.

Results. The patients were comparable in age, hormonal status, major parameters of somatic and gynecological history, parity, and infertility factors. The maximum and minimum number of embryos on day 5, including “high quality” embryos was observed in the Primapur® group (4.24 ± 0.52), and the Puregon® group (2.76 ± 0.37), respectively. In the group of patients using Primapur®, the incidence of clinical pregnancy was 44.0 %, in the group using Gonal-f® – 48.0 %, and in the group using Puregon® – 44.0 %, that did not significant differed between groups (p > 0.05). While assessing the frequency of live births, no significant inter-group differences were found. «Take Home Baby» parameter was 52.0 % in the Gonal-f® group, 60.0 % in the Puregon® group (p > 0.05) that was insignificantly higher in the group of patients treated with biosimilar follitropin alfa (64.0 % ).

Conclusion. The new drug being a biosimilar follitropin alfa does not differ in clinical efficiency from other gonadotropins and can be used for controlled superovulation induction in ART programs.

About the Authors

M. A. Kurtser
Pirogov Russian National Research Medical University, Health Ministry of Russian Federation
Russian Federation

Mark A. Kurtser – МD, Dr Sci Med, Professor, Academician of RAS, Head of the Department of Obstetrics and Gynecology, Faculty of Pediatrics

1 Ostrovityanova Str., Moscow 117997



G. V. Kasyanova
Lapino Clinical Hospital, Group of Companies «Mother and Child»
Russian Federation

Galina V. Kasyanova – МD, Reproductologist

111, 1st Uspenskoe Highway, Lapino, Odintsovo District, Moscow region 143081



M. M. Ovchinnikova
Lapino Clinical Hospital, Group of Companies «Mother and Child»
Russian Federation

Maria M. Ovchinnikova – МD, Obstetrician-Gynecologist, Reproductologist

111, 1st Uspenskoe Highway, Lapino, Odintsovo District, Moscow region 143081

 



D. T. Khetagurova
Pirogov Russian National Research Medical University, Health Ministry of Russian Federation
Russian Federation

Diana T. Khetagurova – МD, Postgraduate Student

1 Ostrovityanova Str., Moscow 117997



References

1. Chebotnikova T.V. Gonadotropiny: istoriya sozdaniya. [Gonadotropiny: istoriya sozdaniya]. Vestnik reproduktivnogo zdorov'ya. 2008;(1–2):78–9. (In Russ.).

2. Nazarenko T.A., Mishieva N.G. Infertility and age: ways to solve the problem. [Besplodie i vozrast: puti resheniya problemy]. Moscow: MEDpress-inform, 2014. 211 p. (In Russ.).

3. Krasnopolskaya K.V., Nazarenko T.A. Clinical aspects of the infertility treatment in marriage. Diagnosis and therapeutic programs using methods for restoring natural fertility and assisted reproductive technologies: a guide. [Klinicheskie aspekty lecheniya besplodiya v brake. Diagnostika i terapevticheskie programmy s ispol'zovaniem metodov vosstanovleniya estestvennoj fertil'nosti i vspomogatel'nyh reproduktivnyh tekhnologij]. Moscow: GEOTAR-Media, 2013. 376 p. (In Russ.).

4. Gianaroli L., Geraedts J., Veiga A., Simon B. The 'father of IVF' and a founding father of ESHRE. Hum Reprod. 2010;25(12):2933–5. https://doi.org/10.1093/humrep/deq331.

5. Kasyanova G.V., Kurtser M.A., Lebedeva E.G., Mladova E.S. Natural cycle in vitro fertilization: pro and contra. [Ekstrakorporal'noe oplodotvorenie v estestvennom cikle: za i protiv]. Voprosy ginekologii, akusherstva i perinatologii. 2013;12(4):10–16. (In Russ.).

6. Nazarenko T.A., Krasnopolskaya K.V. "Poor response". [«Bednyj otvet»]. Moscow: MEDpress-inform, 2012. 75 p. (In Russ.).

7. Marci R., Caserta D., Lisi F. et al. In vitro fertilization stimulation protocol for normal responder patients. Gynecol Endocrinol. 2013;29(2):109–12. https://doi.org/10.3109/09513590.2012.712002.

8. Order of the Ministry of Health of the Russian Federation No. 107n dated August 30, 2012 “On the procedure for using assisted reproductive technologies, contraindications and restrictions on their use”. Moscow, 2012. 61 p. (In Russ.). Available at: https://arhgkb6.ru/media/2019/07/19/1260979371/Prikaz_Minzdrava_Rossii_N_107n_o_poryadke_ispol_zovaniya_VRT.pdf.

9. Rudakova E.B., Zamakhovskaya L.Y., Strizhova T.V. et al. Outcomes of in vitro fertilization as a multifactorial clinical problem or reproductive medicine. Meditsinskiy sovet. 2015;(9):84–91. (In Russ.). https://doi.org/10.21518/2079-701X-2015-9-84-91.

10. Kulakov I.I., Leonov B.V., Kuzmichev L.N., Smolnikova V.Yu. Treatment of female and male infertility. Assisted reproductive technologies. [Lechenie zhenskogo i muzhskogo besplodiya. Vspomogatel'nye reproduktivnye tekhnologii]. Moscow: MIA, 2005. 592 p. (In Russ.).

11. Anshina M.B., Isakova E.V., Kalinina E.A. et al. Ovarian hyperstimulation syndrome. Clinical guidelines. [Sindrom giperstimulyacii yaichnikov. Klinicheskie rekomendacii]. Problemy reprodukcii. 2013;19(2):8-14. (In Russ.).

12. Hamdine O., Eijkemans M.J., Lentjes E.W. et al. Ovarian response prediction in GnRH antagonist treatment for IVF using anti-Müllerian hormone. Hum Reprod. 2015;30(1):170–8. https://doi.org/10.1093/humrep/deu266.

13. The Human Fertilization and Embryology Authority (HFEA) of Great Britain Faces Expanding Storage Time for Cryopreserved Human Embryos. Available at: http://hdl.handle.net/10822/890699.

14. Guidance for Industry Bioequivalence Recommendations for Specific Products. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). June 2010. 7 p. Available at: https://www.fda.gov/media/71401/download.

15. Strowitzki T., Kuczynski W., Mueller A., Bias P. Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study. Reprod Biol Endocrinol. 2016;14(1):31. https://doi.org/10.1186/s12958-016-0164-y.

16. Rombauts L. Is there a recommended maximum starting dose of FSH in IVF? J Assist Reprod Genet. 2007;24(8):343–9. https://doi.org/10.1007/s10815-007-9134-9.

17. Rettenbacher M., Andersen A.N., GarciaVelasco J.A. et al. A multi-centre phase 3 study comparing efficacy and safety of Bemfola(®) versus Gonal-f(®) in women undergoing ovarian stimulation for IVF. Reprod Biomed Online. 2015;30(5):504–13. https://doi.org/10.1016/j.rbmo.2015.01.005.

18. Kamilova D.P., Ovchinnikova M.M., Ablyaeva E.Sh. et al. An observational study «FOLLITROPIN» comparing the efficacy of follitropin alpha biosimilar: the real-world data. [Effektivnost' primeneniya bioanalogovogo follitropina al'fa v real'noj klinicheskoj praktike: rezul'taty nablyudatel'nogo issledovaniya «FOLLITROPIN»]. Obstetrics, Gynecology and Reproduction. 2021;15(1):5–21. (In Russ.). https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.212.

19. Kvashnina E.V., Askerov R.A., Maiasina E.N. Take-home baby rate as a criteria of IVF quality. The analysis of pregnant women. [Take-home baby – kriterij ocenki kachestva tekhnologii EKO, ocenka gruppy beremennyh zhenshchin]. Problemy reprodukcii. 2012;18(2):68–71. (In Russ.).

20. Perova K.A., Shchurov D.G., Blinov D.V. et al. Pharmacoeconomic analysis of the application of follitropin alfa in combination with assisted reproductive technologies. [Farmakoekonomicheskij analiz primeneniya follitropina al'fa pri ispol'zovanii vspomogatel'nyh reproduktivnyh tekhnologij]. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022;15(1):4050. (In Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.129.


Review

For citations:


Kurtser M.A., Kasyanova G.V., Ovchinnikova M.M., Khetagurova D.T. Retrospective comparative study on artificial reproductive technology outcomes in women undergoing in vitro fertilization with recombinant gonadotropins. Obstetrics, Gynecology and Reproduction. 2022;16(3):277-286. (In Russ.) https://doi.org/10.17749/2313-7347/ob.gyn.rep.2022.304

Views: 133


ISSN 2313-7347 (Print)
ISSN 2500-3194 (Online)